GlycoMimetics, Inc. announced that its stockholders have approved a proposed merger with Crescent Biopharma, Inc., along with all related proposals. At a special meeting held on June 5, 2025, stockholders also approved a 1-for-100 reverse stock split, which will reduce the number of outstanding common stock from approximately 64.5 million shares to about 0.6 million shares. Following the anticipated closing of the merger, the combined company's stock will trade under the new name "Crescent Biopharma, Inc." with the ticker symbol "CBIO" on Nasdaq, beginning June 16, 2025. The total issued and outstanding common stock of the combined company is expected to be approximately 14.8 million shares, or roughly 25.3 million shares on a fully-diluted basis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.